RhoVac reports patient recruitment for phase I/II study is now complete
RhoVac AB ("RhoVac") announced today, July 3 2017, that a total of 22 patients were recruited for company's clinical I/II study. Patient recruitment for this phase of study is not terminated.RhoVac’s phase I/II clinical trial started in early 2017 and first patient was dosed in April. The study focuses on patients with diagnosed prostate cancer in control phase. The primary objective of the study is to evaluate the safety of RV001 vaccine therapy and the secondary goal is to evaluate the immune response in treatment with the cancer vaccine RV001. As proposed in the clinical trial